Chronic inflammation and cancer: Suppressing the suppressors

Michal Baniyash*, Moshe Sade-Feldman, Julia Kanterman

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

87 Scopus citations


Chronic inflammation typical to various chronic diseases is associated with immunosuppression, mediated primarily by immature myeloid-derived suppressor cells (MDSCs). A variety of factors induce MDSC differentiation arrest, thus manipulating the host's immune function and suppressing the innate and adaptive immune systems, as reflected by their impaired status associated with down-regulated expression of the CD247 molecule. Such chronic inflammation-induced immunosuppressive features are also found in many tumors, generating tumor micro- and macro-environments that act as critical barriers to effective anti-tumor responses and therapies. This knowledge offers new and novel candidate immune targets for therapeutic interventions, in combination with more conventional approaches as chemotherapy, radiotherapy, and cancer cell targeted therapy. Therapeutic manipulation of chronic inflammation during cancer development is likely to enhance efficacy of treatments such as vaccinations, and adoptive T cell transfer, thus switching the chronic pro-cancer inflammatory environments into an anti-cancer milieu. Based on the functional relevance of immune networking in tumors, it is advantageous to merge monitoring immune biomarkers into the traditional patient's categorization and treatment regiments, which will provide new prognostic and/or predictive tools to clinical practice. A better identification of environmental and tumor-specific inflammatory mechanisms will allow directing the clinical management of cancer toward a more personalized medicine.

Original languageAmerican English
Pages (from-to)11-20
Number of pages10
JournalCancer Immunology, Immunotherapy
Issue number1
StatePublished - Jan 2014

Bibliographical note

Funding Information:
Acknowledgments we gratefully acknowledge the support of the society of Research associates of the Lautenberg Center, the Concern Foundation of Los angeles, and the harold B. abramson Chair in Immunology. This study was supported by the Israel science foundation (IsF), the Israeli Ministry of health, the Joint German-Israeli Research Program (DKFZ-MOsT), the Israel Cancer Research Fund (ICRF), and the united states-Israel Binational science Foundation (BsF) and by the Joseph and Matilda Melnick Funds. we thank Dr. Lynn wang for reading and commenting on the manuscript.


  • Anti-cancer therapy
  • CITIM 2013
  • Cancer
  • Chronic inflammation
  • Immunosuppression
  • Myeloid-derived suppressor cells


Dive into the research topics of 'Chronic inflammation and cancer: Suppressing the suppressors'. Together they form a unique fingerprint.

Cite this